The abnormal and the pathological: Cholesterol, statins, and the threshold of disease

Medicating Modern America: Prescription Drugs in History

Volumn , Issue , 2007, Pages 183-228

  Greene, Jeremy A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900211584     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (208)

1. Ira S. Nash, Lori Mosca, Roger Blumenthal, Michael H. Davidson, Sidney C. Smith, Jr., Richard C. Pasternak, "Contemporary Awareness and Understanding of Cholesterol as a Risk Factor: Results of an American Heart Association NationalSurvey," Archives of Internal Medicine 163 (2003)13: 1597-1600;
2. R. M. Pieper, D. K. Arnett, P. G. McGovern, E. Shahar, H. Blackburn, and R. V. Luepker, "Trends inCholesterol Knowledge and Screening and Hypercholesterolemia Awareness andTreatment, 1980-1992, The Minnesota Heart Study," Archives of Internal Medicine 157 (1997)20: 2326-32;
3. Earl S. Ford, Ali H. Mokdad, Wayne H. Giles, George A. Mensah, "Serum Total Cholesterol Concentrations and Awareness, Treatment, andControl of Hypercholesterolemia Among US Adults: Findings From the NationalHealth and Nutrition Survey, 1999 to 2000," Circulation 107 (2003): 2185-9.
4. Harry M. Marks, The Progress of Experiment: Science and Therapeutic Reform in the United States, 1900-1990 (Cambridge: Cambridge University Press, 1997).
5. David Healy, The Antidepressant Era (Cambridge: Harvard University Press, 1995).
6. Keith Wailoo, Drawing Blood: Technology and Disease Identity in Twentieth-CenturyAmerica (Baltimore: Johns Hopkins University Press, 1997).
7. Chris Feudtner, Bittersweet: Diabetes, Insulin, and the Transformation of Illness (Chapel Hill: Universityof North Carolina Press, 2003).
8. Robert Kaiser, "The Introduction of theThiazides: A Case-Study in 20th Century Therapeutics," in The Inside Story ofMedicines, ed. Greg Higby and Elaine Stroud (Madison: American Institute of theHistory of Pharmacy, 1997), 121-137;
9. Rein Vos, Drugs Looking for Diseases: InnovativeDrug Research and the Development of the Beta Blockers and the CalciumAntagonists (Dordrecht: Kluwer Academic Publishers, 1990).
10. Maren Klawiter, "Risk, prevention, and the breast cancer continuum: the NCI, the FDA, health activism, and the pharmaceutical industry," History and Technology 18(2002): 309-353
11. Merwyn Susser, "Epidemiology in the United States after World War II: The Evolution of Technique," Epidemiologic Reviews 7(1985): 147-177
12. Robert Aronowitz, Making Sense of Illness: Science, Society, and Disease (New York: CambridgeUniversity Press, 1998), 111-144.
13. George Rosen, Preventive Medicine in the United States (New York: Science History Publications, 1975).
14. Alexander M. Campbell, "The Necessity for a Periodical Examination of the Apparently Healthy," DetroitMedical Journal, 4 (1904): 193-5.
15. Haven Emerson, "The Protection of Health byPeriodic Medical Examinations," Journal of the Michigan State Medical Society, 21 (1922): 158-171.
16. Arjun Appadurai, "Introduction: Commodities and the Politics of Value," in Appadurai, ed., The Social Life ofThings: Commodities in Cultural Perspective (Cambridge: Cambridge UniversityPress, 1988), pp. 3-63.
17. Harry F. Dowling, Medicines for Man: the Development, Regulation, and Use of PrescriptionDrugs (New York: Knopf, 1970).
18. John Lesch, "Chemistry and Biomedicine in anIndustrial Setting: The Invention of the Sulfa Drugs," in Seymour H. Mauskopf, ed., Chemical Sciences in the Modern World (Philadelphia: University of PennsylvaniaPress, 1993), pp. 158-215;
19. Gladys Hobby, Penicillin, Meeting the Challenge (New Haven: Yale University Press, 1985).
20. Jonathan Liebenau, MedicalScience and Medical Industry (Baltimore: Johns Hopkins University Press, 1987).
21. Susan L. Speaker, "From HappinessPills to National Nightmare: Changing Cultural Assessment of Minor Tranquilizersin America, 1955-1980," Journal of the History of Medicine 52 (1997): 338-377.
22. Jordan Goodman and Vivien Walsh, The Story of Taxol: Nature and Politicsin the Pursuit of an Anti-Cancer Drug (Cambridge: Cambridge UniversityPress, 2001).
23. William E. Cox, Jr. "Product Life Cycles as Marketing Models," The Journal of Business 40 (1967): 376-81.
24. Olivia Williams, Anne-Marie Jacks, Jim Davis, Sabrina Martinez, "Merck(A) Mevacor," (unpublished case-study, University of Michigan Business School, September 2002).
25. Olivia Williams, Anne-Marie Jacks, Jim Davis, Sabrina Martinez, "Merck(B) Zocor," (unpublished case-study, University of Michigan BusinessSchool, September 2002).
26. Rita Rubin, "Drugmakers Prescribe Move: Cholesterol Treatments Could BeFirst for Chronic Condition to Shift to OTC," USA Today, June 27, 2000, 1E.;
27. "Merck seeks over-the counter status for anticholesterol drug," The BostonGlobe, April 7, 1999, E5.
28. "Drugmakers Prescribe Move," 1D.
29. Allan S. Brett, "Psychologic effects of the diagnosis and treatment of hypercholesterolemia: Lessons from case studies," American Journal of Medicine 91 (1991): 642-7.
30. see R. C. Lefebvre, K. G. Hursey, R. A. Carleton, "Labeling ofparticipants in high blood pressure screening programs: implications for bloodcholesterol screenings," Archives of Internal Medicine 148 (1988): 1993-7.
31. T. Tijmstra, "The psychological and social implications of serum cholesterol screening," International Journal of Risk and Safety in Medicine 1 (1990): 29-44.
32. Jeffrey L. Anderson, Department of Health and HumanServices, Food and Drug Administration, Public Hearing on FDA Regulation of Over-the-Counter Drug Products, June 29, 2000, FDA Docket 00N-1256, pp. 111-12.
33. Public Hearing on FDA Regulation of Over-the-Counter Drug Products, June 29, 2000, 7-8.
34. Rubin, "Drugmakers Prescribe Move." Data on Lipitormarket share from IMS Health, "Developments in the Statin Market,"March 16, 2000.
35. Edward Frohlich, Public Hearing on FDA Regulation of Overthe-Counter Drug Products, June 29, 2000, 131-3.
36. Cross-examination, Robert Temple, ibid., 139-140.
37. "Panel Retains Status of Cholesterol Drugs," New York Times, July 18, 2000, F12
38. Elizabeth Mechcatie, "FDA PanelRejects Making Low-Dose Statins Available OTC," Family Practice News, September 1, 2000.
39. Lawrence K. Altman, "Report about Cholesterol DrawsAgreement and Dissent," New York Times, May 28, 1980, D18;
40. Jane E. Brody, "Disputeon Americans' Diets," New York Times, May 29, 1980; D18;
41. Brody, "WhenScientists Disagree, Cholesterol Is in Fat City," New York Times, June 1, 1980, E1;
42. "A Confusing Diet of Fact," New York Times, June 2, 1980, A18;
43. Karen De Witt, "Scientists Clash on Academy's Cholesterol Advice," New York Times, June 20, 1980, A15;
44. Charles E. Rodgers, Jr., "Cholesterol Diets: A New Low," New YorkTimes, June 29, 1980, WC18;
45. Victor Herbert, "In Defense of the Cholesterol Report," New York Times, July 13, 1980.
46. Patricia Hausman, Jack Sprat's Legacy: The Science and Politics of Fat & Cholesterol (New York: Richard Marek, 1981).
47. Marion Nestle, Food Politics: Howthe Food Industry Influences Nutrition and Health (Berkeley: University of CaliforniaPress, 2001).
48. Thomas R. Dawber, Felix Moore, and George V. Mann, "Coronary HeartDisease in the Framingham Study," American Journal of Public Health (April, 1957): 3-24;
49. Thomas R. Dawber, Gilcin F. Meadors, and Felix Moore, "Epidemiologic Approaches to Heart Disease: The Framingham Study," AmericanJournal of Public Health 41 (1951): 279-286.
50. Thomas R. Dawber, The Framingham Study: The Epidemiology of Atherosclerotic Disease (Cambridge: HarvardUniversity Press, 1980)
51. A. Keys and K. T. Anderson, "The Relationship of the Dietto the Development of Atherosclerosis in Man," in Symposium on Atherosclerosis (Washington, DC: National Academy of Sciences, 1954), 181-187;
52. Norman Joliffe, "Fats, Cholesterol, and Coronary Heart Disease: A Review of RecentProgress," Circulation, 20 (1959): 109-127.
53. A. Kagan, B. R. Harris, W. Winkelstein, Jr., "Epidemiological Studies of Coronary Heart Disease and Stroke in JapaneseMen Living in Japan, Hawaii, and California: Demographic, Physical, Dietary, andBiochemical Characteristics," Journal of Chronic Disease 27 (1974): 345-364.
54. W. B. Kannel, W. P. Castelli, T. Gordon, "Cholesterol in the Prediction of AtheroscleroticDisease," Annals of Internal Medicine 90 (1979): 85-91.
55. A. Keys, C. Aravanis, H. Blackburn, Seven Countries: A Multivariate Analysis of Death and Coronary HeartDisease (Cambridge: Harvard University Press, 1980).
56. Jeremy A. Greene, "Releasing the Flood Waters: Diuril and the Reshapingof Hypertension," Bulletin of the History of Medicine (2005) 79(4): 749-94.
57. Lipid Research Clinics Program, "The Lipid Research Clinics CoronaryPrevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease," Journal of the American Medical Association 251(1984)3: 351-364;
58. Consensus Conference, "Lowering Blood Cholesterol to Prevent Heart Disease," Journal of theAmerican Medical Association 253(1985)14: 2080-2086.
59. Jeremy A. Greene, "The Therapeutic Transition: Pharmaceuticals and the Marketing ofChronic Disease" (Harvard: PhD diss., 2005).
60. Karin Garrety, "Social Worlds, Actor-Networks and Controversy: The Case of Cholesterol, Dietary Fat, and Heart Disease," Social Studies of Science 27 (1997): 727-773.
61. Jonathan R. Cole, "Dietary Cholesterol and Heart Disease: The Construction of a Medical 'Fact,'" in Surveying Social Life, ed. Hubert J. O. Gorman (Middletown:Wesleyan UniversityPress, 1988), 437-466.
62. Russell L. Cecil, Robert F. Loeb, (Philadelphia, W. B. Saunders, 1955), 702-3;
63. Kendall Emerson, Jr., "Xanthomatosisand Lipidosis," Principals of Internal Medicine, 3rd ed., ed. T. R. Harrison (New York: McGraw-Hill, 1958), 742-745.
64. Howard A. Eder, "Primary Hyper-and Hypolipidemias," Cecil-Loeb Textbookof Medicine, 11th ed., ed. Paul B. Beeson and Walsh McDermott (Philadelphia: W. B. Saunders, 1963), 1334.
65. Elias Amador, "Health and Normality," Journal of the American MedicalAssociation 232(1975)9: 953-4.
66. William E. Stempsey, Disease and Diagnosis: Value-Dependent Realism (Boston: Kluwer AcademicPublishers, 1999).
67. Georges Canguilhem, The Normal and the Pathological, trans. Carolyn R. Fawcett (New York: Zone Books, 1991[1943]), 70.
68. Loren Graham, Between Science and Values (New York: Columbia University Press, 1981).
69. Theodore M. Porter, The Rise ofStatistical Thinking: 1820-1990 (Princeton: Princeton University Press, 1986).
70. Ian Hacking, The Taming of Chance (Cambridge: Cambridge University Press, 1990).
71. J. Rosser Matthews, Quantification and the Quest for Medical Certainty (Princeton: Princeton UniversityPress, 1995).
72. William G. Rothstein, Public Health and the Risk Factor: A Historyof an Uneven Medical Revolution (Rochester: University of Rochester Press, 2003), 36-49.
73. Daniel Steinberg and Antonio Gotto, "Preventing Coronary Artery Diseaseby Lowering Cholesterol Levels: Fifty Years from Bench to Bedside," Journal of theAmerican Medical Association 282 (1999)21: 2043-50.
74. J. Stuart, "Any mancan have a heart attack," Today's Health, November 1961, 12-13;
75. L. Kavaler, "Willthere soon be a drug that might ultimately prolong your husband's life?" GoodHousekeeping, October 1969, 112-3ff.;
76. "Drug to prevent heart attacks?" U.S. News & World Report, July 8, 1968, 13.
77. Allan Brandt, "Behavior, Disease, and Health in the Twentieth-Century United States: TheMoral Valence of Individual Risk," and Charles Rosenberg, "Banishing Risk: Continuityand Change in the Moral Management of Disease," in Allan M. Brandtand Paul Rozin, eds., Morality and Health (London: Routledge, 1997), 35-52, 53-79;
78. Rosenberg, "Pathologies of Progress: The Idea of Civilization as Risk," Bulletin of the History of Medicine 72 (1998)4: 714-30.
79. Maxwell M. Wintrobe, George W. Thorn, Raymond D. Adams, Ivan L. Bennett, Eugene Braunwald, Kurt J. Isselbacher, and Robert G. Petersdorf (NewYork: McGraw-Hill, 1970), 630.
80. Kurt J. Isselbacher, Raymond D. Adams, EugeneBraunwald, Robert G. Petersdorf, and Jean D. Wilson (New York: McGraw-Hill, 1980), 507-518, quotation p. 507.
81. John A. Byrne, "The Miracle Company," Business Week, October 19, 1987, 88.
82. "Cholesterol breakthrough: Mevacor caps a decades-long research effort," Merck World 8(1987)5: 4-13, quotationp. 13.
83. Eugene Braunwald, Kurt J. Isselbacher, Robert J. Petersdorf, Jean D. Wilson, Joseph B. Martin, and Anthony S. Fauci (New York: McGraw-Hill, 1987), 1658.
84. "Cholesterol breakthrough: Mevacor caps a decades-long research effort," quotation p. 13.
85. D. W. Bilheimer, S. M. Grundy, M. S. Brown, J. L. Goldstein, "Mevinolin andcolestipol stimulate receptor-mediated clearance of low density lipoprotein fromplasma in familial hypercholesterolemia heterozygotes," Proceedings of theNational Academy of Sciences of the United States of America 80 (1983)13: 4124-8;
86. S. M. Grundy, D. W. Bilheimer, "Inhibition of 3-hydroxy-3-methylglutaryl-CoAreductase by mevinolin in familial hypercholesterolemia heterozygotes: effects oncholesterol balance," Proceedings of the National Academy of Sciences of the UnitedStates of America 81 (1984): 2538-42.
87. D. R. Illingworth, G. J. Sexton, "Hypercholesterolemiceffects of mevinolin in patients with heterozygous familial hypercholesterolemia," Journal of Clinical Investigation 74 (1984): 1972-8.
88. J. M. Hoeg, M. B. Maher, L. A. Zech, K. R. Bailey, R. E. Gregg, K. J. Lackner, S. S. Fojo, M. A. Anchors, M. Bojanovski, D. L. Sprecher, et al., "Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia," AmericanJournal of Cardiology 57 (1986): 933-9.
89. R. J. Havel, D. B. Hunninghake, D. R. Illingworth, R. S. Lees, E. A. Stein, J. A. Tobert, S. R. Bacon, J. A. Bolognese, P. H. Frost, G. E. Lamkin, et al., "Lovastatin (mevinolin) in the treatment of heterozygousfamilial hypercholesterolemia. A multicenter study," Annals of Internal Medicine 107 (1987)5: 609-15.
90. C. East, S. M. Grundy, D. W. Bilheimer, "Normalcholesterol levels with lovastatin (mevinolin) therapy in a child with homozygousfamilial hypercholesterolemia following liver transplantation," Journal of theAmerican Medical Association 256 (1986): 2843-8.
91. C. A. East, S. M. Grundy, D.W. Bilheimer, "Preliminary report. Treatment of type 3 hyperlipoproteinemia withmevinolin," Metabolism 35 (1986): 7-8;
92. G. L. Vega, C. A. East, S. M. Grundy, "Lovastatin therapy in familial dysbetalipoproteinemia: effect on kinetics ofapoprotein B," Atherosclerosis 70 (1988): 131-143.
93. A. Garg and S. M Grundy, "Lovastatin for lowering cholesterol levels in noninsulin-dependent diabetes mellitus," New England Journal of Medicine 314 (1988): 81-6.
94. G. L. Vega and S. M. Grundy, "Lovastatin therapy in nephritic hyperlipidemia: effects on lipoproteinmetabolism," Kidney 33 (1988): 1160-8.
95. "Cholesterol breakthrough: Mevacor caps a decades-long research effort," 12.
96. A multicenter study," Journal of the American Medical Association 256 (1986)20: 2829-34;
97. Lovastatin Study Group III, "A multicenter comparison oflovastatin and cholestyramine therapy for severe primary hypercholesterolemia," Journal of the American Medical Association 260 (1988)3: 359-66.
98. Philip J. Hilts, "FDA Approves Sale of More Effective Cholesterol-Lowering Drug," The Washington Post, September 2, 1987, A3.
99. Gotto's extensive institutional affiliations are discussed in Timothy J. Moore, "The Cholesterol Myth," 54.
100. Hilts, "FDA Approves Sale of More Effective Cholesterol-Lowering Drug."
101. "Cholesterol breakthrough: Mevacor caps a decades-long research effort," 13.
102. Reagan H. Bradford, Charles L. Shear, Athanassios N. Chremos, Carlos Dujovne, Frank A. Franklin, Michael Hesney, Jim Higgins, Alexandra Langendorfer, James L. Pool, Harold Schnaper, Wendy P. Stephenson, "Expanded clinical evaluation of lovastatin (EXCEL) study: design and patientcharacteristics of a double-blind, placebo controlled study in patients with moderatehypercholesterolemia," American Journal of Cardiology 66 (1990): 44B-55B.
103. Michael F. Oliver, "Consensus or Nonsensus Conferences on CoronaryHeart Disease," Lancet (1985): 1087-9;
104. Edward H. Ahrens, "The Diet-Heart Questionin 1985: Has It Really Been Settled?" Lancet (1985): 1085-7.
105. R. H. Bradford, C. L. Shear, C. Dujovne, M. Downton, F. A. Franklin, A. L. Gould, M. Hesney, J. Higgins, D. P. Hurley, et al., "Expanded clinical evaluation oflovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins andadverse event profile in 8245 patients with moderate hypercholesterolemia," Archives of Internal Medicine 151 (1991)1: 43-9;
106. R. H. Bradford, C. L. Shear, A. N. Chremos, F. A. Franklin, D. T. Nash, D. P. Hurley, C. A. Dujovne, J. L. K. Pool, H. Schnaper, H. Hesney, et al., "Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managingpatients with moderate hypercholesterolemia," American Journal of Medicine 91(1991)1B: 18S-24S.
107. J. A. Tobert, "New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase," Circulation 76 (1987)3: 534-538.
108. National Cholesterol Education Program, Second Report of the Expert Panelon Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (AdultTreatment Panel II) (Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute, 1993), III3-III10.
109. "Bristol-Myers Gets Approval on Drug," New York Times, November 2, 1991, 39.
110. R. H. Brandford et. al., "Expanded clinical evaluation of lovastatin (EXCEL) study: design and patient characteristics," 45B.
111. Adriana Petryna, "The Human Subjects Research Industry," in AdrianaPetryna, Andrew Lakoff, and Arthur Kleinman (eds.) Global Pharmaceuticals: Ethics, Markets, Practices (Durham, NC: Duke University Press, 2006).
112. J. E. Beach, "Clinical TrialsIntegrity: A CRO Perspective," Accountability in Research 8 (2001)33: 245-60;
113. R. K. H. Wyse and R. G. Hughes, Pharmaceutical Contract Research in the 1990s (London: Technomark Consulting Services, 1993).
114. Fin, "Temporary Help Stretches to Long Term," 5.
115. Clive Cookson, "Survey of Pharmaceuticals," Financial Times, March 23, 1994.
116. K. A. Getz, AMCs Rekindling Clinical Research Partnerships with Industry (Boston: Centerwatch, 1999)
117. Thomas Bodenheimer, "Uneasy Alliance: Clinical Investigators and the Pharmaceutical Industry," New England Journal ofMedicine 342 (2000)20: 1539-1544, p. 1540.
118. Kathleen Day, "Test-Driving Pharmaceuticals: Biometric Research Finds Success in Saving Drug Manufacturers Time andMoney," The Washington Post, March 21, 1994, F5;
119. Cookson, "Survey of Pharmaceuticals."
120. M. R. Weir, M. I. Berger, C. L. Liss, N. C. Santanello, "Comparison ofthe effects on quality of life and of the efficacy and tolerability of lovastatin versuspravastatin: The quality of life multicenter group," American Journal of Cardiology 71 (1993): 810-815.
121. "Merck claims efficacy advantage for statins," Pharma Marketletter, June 1, 1992.
122. Cathy Kelley, Mark Helfand, Chester Good, and Michael Ganz, Drug Class Review: Hydroxymethylglutaryl-coenzyme-AReductase Inhibitors (statins) (Washington, DC:Veterans Health Administration, Pharmacy Benefit Management, Strategic Healthcare Group), 3-10.
123. National Cholesterol Education Program, Second Report of the Expert Panelon Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (AdultTreatment Panel II): Executive Summary, 14-20.
124. American Journal of Cardiology 71 (1993)5: 393-400;
125. Scandinavian SimvastatinSurvival Study Group, "Randomized trial of cholesterol lowering in 4444 patientswith coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)," Lancet 344 (1994)8934: 1383-89.
126. S. Guptha, "Profiling a landmark clinical trial: Scandinavian Simvastatin Survival Study," Current Opinion in Lipidology 6(5) 1995: 251-3.
127. Clive Cookson, "Drugs Improve Heart Patient's Prospects," FinancialTimes, November 18, 1994, p. 4;
128. Gina Kolata "Cholesterol Drugs Found to Save Lives," New York Times, November 17, 1994, A1.
129. "FDA Approves Zocor Label Change," Pharma Marketletter, July 10, 1995;
130. Williams et al., "Merck(B) Zocor."
131. Estimated cost of trial from "Wider Use Seen for Treatment of Cholesterol," New York Times, March 27, 1996, A17.
132. Frank M. Sacks, Marc A. Pfeffer, Lemuel A. Moye, Jean L. Rouleau, John D. Rutherford, Thomas G. Cole, Lisa Brown, J. Wayne Warnica, J. Malcolm O. Arnold, Chuan-Chuan Wun, Barry R. Davis, and Eugene Braunwald, "The Effects of Pravastatinon Coronary Events After Myocardial Infarction in Patients with Average CholesterolLevels," New England Journal of Medicine 335 (1996)14: 1001-9.
133. National Cholesterol Education Program, Cholesterol Lowering in thePatient with Coronary Heart Disease (Bethesda: NHLBI, 1997), 4.
134. "Statin Trial Results Imminent," Pharmaceutical Business News, September 27, 1995.
135. Ron Winslow and Elyse Tanouye, "Bristol-Myers Enters Battle of HeartDrugs," Wall Street Journal, November 16, 1995, B1;
136. J. Shepherd, S. M. Cobbe, I. Ford, et al., "Prevention of coronary heart disease with pravastatin in men withhypercholesterolemia," New England Journal of Medicine 333 (1995)20: 1301-7.
137. Jane E. Brody, "Benefit to Healthy Men Is Seen From Cholesterol-Cutting Drug: Study Finds Reduced Incidence of Heart Attack," New York Times, November 16, 1995, A1.
138. Torje Pedersen, "Lowering Cholesterol with Drugs and Diet," New EnglandJournal of Medicine 333 (1995): 1350-1.
139. "F. D.A. Allows Drug as a Heart Medicine," New York Times, July 9, 1996;
140. "Bristol-Myers Squibb Co.: FDA approves ad claims on drug, first heart attack," Wall Street Journal, July 9, 1996, B6.
141. "Pravachol Helps Prevent First Heart Attacks," two-page advertisement, TheNew York Times, first printed September 8, 1996, 33-34.
142. Milton Liebman, "DTC's Role in the Statin Bonanza," Medical Marketingand Media 36 (2001)11: 86-90.
143. Thomas A. Pearson, "Lipid-Lowering Therapy in Low-Risk Patients," Journal of the American Medical Association 279 (1998)20: 1659-61.
144. J. R. Downs, P. A. Beere, E. Whitney, M. Clearfield, S. Weis, J. Rochen, E. A. Stein, D. R. Shapiro, A. Langendorfer, A. M. Gotto, Jr., "Design and rationale ofthe Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/Tex-CAPS)," American Journal of Cardiology 80 (1997)3: 287-93;
145. J. R. Downs, M. Clearfield, S. Weis, E. Whitney, D. R. Shapiro, P. A. Beere, A. Langendorfer, E. A. Stein, W. Kruyer, A. M. Gotto, Jr., "Primary prevention of acute coronary eventswith lovastatin in men and women with average cholesterol levels: results ofAFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study," Journal of the American Medical Association 279 (1998): 1615-22.
146. "Mevacor Study May Extend Lipid-Lowering Therapy," Pharma Marketletter, November 13, 1997.
147. "Mevacor Approved for Primary Prevention," Pharma Marketletter, March 18, 1999.
148. Margot Mellies and Hartmann Willhoefer, "Current and future clinical trials," in Allan Gaw, Christopher J. Packard, James Shepherd (eds.) Statins: TheHMG CoA Reductase Inhibitors in Perspective (Malden, MA: Martin Dunitz, 2000), 179-201.
149. National Cholesterol Education Program, Third Report of the NationalCholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, andTreatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (Bethesda: National Institutes of Health, NHLBI, 2001).
150. Thomas M. Burton and Chris Adams, "New U.S. Guidelines Would Triple Use of Cholesterol-Lowering Drugs," Wall Street Journal, May 16, 2001, B1.
151. Jeffrey L. Anderson, Merck Research Laboratories, PublicHearing on FDA Regulation of Over-the-Counter Drug Products, June 29, 2000, 108-11.
152. Rita Rubin, "Drugmakers Prescribe Move: Cholesterol Treatments CouldBe First for Chronic Condition to Shift to OTC," USA Today, June 27, 2000;
153. Victoria Stagg, "FDA advisory committee vetoes OTC status for low-dose anti-cholesteroldrugs," AMNews, August 7, 2000.
154. Jerome D. Cohen, St. Louis University, Public Hearing onFDA Regulation of Over-the-Counter Drug Products, June 29, 2000, 84-5.
155. Jeffrey L. Anderson, Merck Research Laboratories, PublicHearing on FDA Regulation of Over-the-Counter Drug Products, June 29, 2000, 107.
156. "Serum total cholesterol (mg/dL) levels for persons 20 years of age orolder, United States, 1988-94," in Third Report of the National Cholesterol EducationProgram (NCEP) Expert Panel on Detection, Evaluation, and Treatment ofHigh Blood Cholesterol in Adults, III-A-1.
157. Stephen B. Hulley, Judith M. B. Walsh, Thomas B. Newman, "Health Policy on Blood Cholesterol: Time to Change Directions," Circulation (1992): 1026-9;
158. George Davey Smith, Juha Pekkanen, "Should therebe a moratorium on the use of cholesterol lowering drugs?" British Medical Journal 304 (1992): 431-4.
159. Peter H. Jones, "Low Serum CholesterolIncreases the Risk of Noncardiovascular Events: An Antagonist Viewpoint," CardiovascularDrugs and Therapy, 8 (1994): 871-4.
160. Scott Allen and Stephen Smith, "Statin Nation: Do we all need to lower our 'bad' cholesterol?" Boston Globe, March 16, 2004;
161. Ron Winslow, "Blood Feud: ForBristol Myers, Challenging Pfizer Was Big Mistake; In Rare Head-to-Head Study, Lipitor Beats Pravachol at Reducing Heart Risk; a New Push on Cholesterol," Wall Street Journal, March 9, 2004, A1.
162. Michael F. Oliver, "Reducing Cholesterol Does Not Reduce Mortality," Journal of the American College of Cardiologists 12 (1988)3: 14-7;
163. Michael F. Oliver, "Might treatment of hypercholesterolaemia increase non-cardiac mortality?" Lancet 337 (1991): 1529-31;
164. Oliver, "Doubts about preventing coronaryheart disease," British Medical Journal 304 (1992): 393-4.
165. Uffe Ravbskov, TheCholesterol Myths: Exposing the Fallacy That Saturated Fat and Cholesterol CauseHeart Disease (Washington, DC: New Trends Publishing, 2000).
166. The Toronto Working Group on Cholesterol Policy, "Asymptomatic Hypercholesterolemia: A Clinical Policy Review," Journal of Clinical Epidemiology 43 (1990)10: 1021-1122.
167. Alan M. Garber, "Where to draw the line against cholesterol," Annals of Internal Medicine 111 (1989): 625-27.
168. A. M. Garber, B. Littenberg, H. C. Sox, M. E. Gluck, J. L. Wagner, and B. M. Duffy, Costs and Effectivenessof Cholesterol Screening in the Elderly, U.S. Congress, Office of TechnologyAssessment (Washington, DC.: U.S. Government Printing Office, 1989).
169. Toronto Working Group on Cholesterol Policy, "Asymptomatic Hypercholesterolemia," 1093.
170. A. Williams, "Screening for risk of CHD: Is it a wise use of resources?" in Screening for Risk of Coronary Heart Disease, ed. M. Oliver, M. Ashley Miller, D. Wood (London: John Wiley & Sons, 1986), 97-106;
171. G. Oster, A. M. Epstein, "Cost-effectiveness of antihyperlipidemic therapy in the prevention of coronaryheart disease: the case of cholestyramine," Journal of the American Medical Association 258(1987): 2381-7.
172. William Taylor, "Screening for High BloodCholesterol and Other Lipid Abnormalities," in Guide to Clinical Preventive Services: Report of the U S. Preventive Services Task Force, 2nd ed. (Baltimore: Williams & Wilkins, 1989).
173. P. Doubilet, M. C. Weinstein, and B. J. McNeil, "Use and misuse of the term 'cost-effective' in medicine," New England Journal of Medicine 314 (1986): 253-6.
174. G.W. Torrance, "Measurement of health states utilities for economic appraisal: review," Journal of Health Economics 5 (1986): 1-30;
175. D. U. Himmelstein, S. Woolhandler, "Free care, cholestyramine, and health policy," New England Journal ofMedicine 311(1984): 1511-14;
176. M. C. Weinstein, W. B. Stason, "Cost-effectivenessof interventions to prevent or treat coronary heart disease," Annual Review ofPublic Health 6 (1985): 41-63.
177. AmericanHeart Journal 119 (1990): 718-24;
178. M. D. Kelley, "Hypercholesterolemia: thecost of treatment in perspective," Southern Medical Journal 83 (1990)12: 1421-5;
179. L. Goldman, M. C. Weinstein, P. A. Goldman, L. W. Williams, "Cost-effectivenessof HMG-CoA reductase inhibition for primary and secondary prevention ofcoronary heart disease," Journal of the American Medical Association 265 (1991): 1145-51.
180. Jonathan S. Silberberg and David A. Henry, "The benefits of reducingcholesterol levels: the need to distinguish primary from secondary prevention," Medical Journal of Australia 155 (1991): 665-674.
181. Ivar S. Kristiansen, Anne E. Eggen, Dag S. Thelle, "Cost effectiveness of incremental programmes for loweringserum cholesterol concentration: is individual intervention worth while?" BritishMedical Journal 302 (1991): 1119-22.
182. Second Report of the Expert Panel on Detection, Evaluation, and Treatmentof High Blood Cholesterol in Adults (Adult Treatment Panel II): Final Report, IV-13.
183. M. C. Weinstein, "From cost-effectiveness ratios to resource allocation: where to draw the line?" in Valuing Health Care: Costs, Benefits, andEffectiveness of Pharmaceuticals and Other Medical Technologies, ed. F. A. Sloan (New York: Cambridge University Press, 1995).
184. Goldman, D. J. Gordon, B. M. Rifkind, S. B. Hulley, A. S. Detsky, D. W. Goodman, B. Kinosian, M. C. Weinstein, "Cost and health implications of cholesterollowering," Circulation 85 (1992)5: 1960-8.
185. J. Lyle Bootman, Raymond J. Townsend, William F. McGhan, Principles of Pharmaco economics (Cincinnati: Harvey Whitney Books, 2001).
186. J. W. Hay, E. H. Wittels, A. M. Gotto, Jr., "An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction," American Journal of Cardiology 67 (1991)9: 789-96, quotation p. 789.
187. D. Thompson and G. Oster, "Cost-effectiveness of drug therapy forhypercholesterolaemia: a review of the literature," Pharmaco economics 2 (1992)1: 34-42;
188. "Cholesterol Pill Linked to Lower Hospital Bills," New York Times, March 27, 1995;
189. R. B. Goldberg, M. J. Mellies, F. M. Sacks, et al., "Cardiovascular events and their reduction with pravastatin in diabeticand glucose-intolerant myocardial infarction survivors with average cholesterollevels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial," Circulation 98 (1998): 2513-19.
190. J. Caro, W. Klittich, A. McGuire, et al., "The West of Scotland Coronary Prevention Study: weighing the costs andbenefits of primary prevention with pravastatin," British Medical Journal 315 (1997): 1577-84.
191. A. M. Gotto, S. J. Boccuzzi, J. R. Cook, C. M. Alexander, J. B. Roehm, G. S. Meyer, M. Clearfield, S. Weis, E. Whitney, "Effect of lovastatin oncardiovascular resource utilization and costs in the Air Force/Texas CoronaryAtherosclerosis Prevention Study (AFCAPS/TexCAPS)" American Journal of Cardiology 86(2000)11: 1176-81.
192. David Atkins and Carolyn DiGuiseppi, "Screening for High Blood Cholesterol and Other Lipid Abnormalities," in Guide to Clinical Preventive Services: Report of the U.S. Preventive Services Task Force, 2nd ed., ed. Carolyn DiGuiseppi, David Atkins, and Steven H. Woolf (Baltimore:Williams & Wilkins, 1996), 15-38;
193. L. A. Prosser, A. A. Stinnett, P. A. Goldman, et al., "Cost-effectiveness ofcholesterol-lowering therapies according to selected patient characteristics," Annals of Internal Medicine 132(2000): 769-79.
194. M. Johannesson, "Economic evaluation of lipid lowering-a feasibilitytest of the contingent evaluation approach," Health Policy 20(1992)3: 309-20.
195. J. M. Gaspoz, J. W. Kennedy, E. J. Orav, L. Goldman, "Cost-effectiveness of prescription recommendations for cholesterol-lowering drugs: a survey of a representative sample of American cardiologists," Journal of the American College of Cardiology 27 (1996)5: 1232-7.
196. M. Mitka, "Expanding statin use to help more at-risk patients is causingfinancial heartburn," Journal of the American Medical Association 290(2003)17: 2243-5.
197. Mickey Smith, Small Comfort: A History of the Minor Tranquilizers (NewYork: Praeger, 1985).
198. Klawiter, "Risk, prevention, and the breast cancer continuum: the NCI, the FDA, health activism, andthe pharmaceutical industry."
199. Clifton Meador, "The last well person," New England Journal of Medicine 330(1994): 440-1;
200. Victoria Stagg Elliott, "Are we all sick? Doctors debate the 'medicalization' of life," AMNews, September 20, 2004.
201. Mickey C. Smith's Small Comfort: AHistory of the Minor Tranquilizers (New York: Praeger Scientific, 1985).
202. David Rothman and Sheila Rothman, The Pursuit of Perfection: The Promiseand Perils of Medical Enhancement (New York: Random House, 2004).
203. Carl Elliott, Better than Well: American Medicine Meets the American Dream (NewYork:W.W. Norton, 2003).
204. David Noonan, "You want statins with that?" Newsweek, July 14, 2004.
205. Chris Feudtner, "The Want of Control: Ideas, Innovations, and Ideals in the Modern Managementof Diabetes Mellitus," Bulletin of the History of Medicine 69(1995): 66-90.
206. Sylvia Carter, "New York Strip House," New York Newsday, November 23, 2001;
207. John S. Long "Friday!" Cleveland Plain Dealer, October 1, 2004, 20.
208. Al Branch, Jr., "J&J/Merck Seek OTC Status for Mevacor," Pharmaceutical Executive, November 2002, 22.